Bristol-Myers Squibb Foundation Awards $1.5 Million in Grants

Bristol-Myers SquibbThe Bristol-Myers Squibb Foundation awarded five grants totaling $1.5 million to organizations that will empower African American women with type 2 diabetes to better manage their disease while also leveraging their standing as leaders in their families and communities to influence the health of those around them.

The grants are part of Together on Diabetes® a five-year, $100 million initiative to improve health outcomes of people living with type 2 diabetes in the United States by strengthening patient self-management education, community-based supportive services and broad-based community mobilization. Consistent with the Bristol-Myers Squibb Foundation's mission to reduce health disparities, the initiative targets adults disproportionately affected by type 2 diabetes.

The U.S. Centers for Disease Control and Prevention estimates that one in 10 African American women age 20 and older has diabetes, a rate that more than doubles to one in four for African American women over 55. African Americans also suffer high rates of diabetes' most serious complications such as blindness, kidney failure and amputation.

"African American women represent one of the country's highest risk groups for developing and suffering the impact of type 2 diabetes," says Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. "With these grants specifically focused on African American women, Together on Diabetes® is supporting innovative efforts to make self management programs work for African American women in the context of their lives."

As president and CEO of the Black Women’s Health Imperative, Eleanor Hinton Hoytt is on the front lines in the battle against type 2 diabetes in the African American community. "With diabetes reaching epidemic proportions among black women nationwide, we cannot underestimate the importance of innovative public-private partnerships that support community-driven health initiatives," says Ms. Hinton Hoytt.

"As a national organization dedicated to advancing the health and wellness of black women, we at the Black Women’s Health Imperative have seen firsthand the devastating toll diabetes has taken on the population we serve. Through this unique partnership with the Bristol-Myers Squibb Foundation, we and our fellow grantees now have the opportunity to build on experience designing gender and culturally specific health initiatives and demonstrate the effectiveness of a self-care management model that empowers black women to take charge of their health."

About the Bristol-Myers Squibb Foundation
The Bristol-Myers Squibb Foundation is an independent 501(c)(3) charitable organization whose mission is to reduce health disparities and improve health outcomes around the world for patients disproportionately affected by serious disease.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...

Another mRNA-based vaccine candidate protects anim…

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and no...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Pfizer and BioNTech announce an agreement with U.S…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of...

Pfizer and BioNTech announce agreement with the Un…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candid...

Pfizer and BioNTech choose lead mRNA vaccine candi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a singl...